Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Use of PIs among 679 subjects initiating PI-based HAART for HIV/AIDS at St Paul's Hospital, Vancouver, BC, August 1996 – January 2002

From: Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS

Characteristic*

 

Number of months between initiation of PI and end of observation, median (IQR)**

47 (29–62)

% of follow-up time with dispensed therapy mean (SD), median for PI

73 (30) 84

Mean (SD) number prescriptions for***

 

PI

31 (19)

% adherence in first year

 

mean (SD)

89 (21)

median (IQR)

100 (92 – 100)

  1. Abbreviations: SD = Standard deviation; IQR = Interquartile range; NRTI = nucleoside reverse transcriptase inhibitors; PI protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor
  2. * PIs available during follow-up included: indinavir, nelfinavir, saquinavir, and ritonavir. All data taken from time of first therapy initiation (treatment program enrollement).
  3. ** Time between first dispensation of HAART (enrollment) and last date of follow-up.
  4. *** All prescriptions are of 30 day duration
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X